Insider Selling: GeneDx (NASDAQ:WGS) CFO Sells 3,728 Shares of Stock

Key Points

• Kevin Feeley, CFO of GeneDx (NASDAQ:WGS), sold 3,728 shares of the company at an average price of $121.47, amounting to approximately $452,840, reducing his ownership by nearly 30%.
• GeneDx's stock recently traded up to $130.71, showing strong price performance after a yearly low of $35.88 and high of $136.00.
• Analysts have a consensus rating of "Moderate Buy" for GeneDx, with price targets ranging from $95.00 to $140.00, reflecting positive sentiment towards the company's growth potential.

GeneDx Holdings Corp. (NASDAQ:WGS - Get Free Report) CFO Kevin Feeley sold 3,728 shares of the firm's stock in a transaction that occurred on Tuesday, September 16th. The shares were sold at an average price of $121.47, for a total value of $452,840.16. Following the completion of the sale, the chief financial officer directly owned 8,755 shares of the company's stock, valued at $1,063,469.85. This trade represents a 29.86% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Kevin Feeley also recently made the following trade(s):

• On Tuesday, September 2nd, Kevin Feeley sold 378 shares of GeneDx stock. The stock was sold at an average price of $125.81, for a total value of $47,556.18.
• On Tuesday, July 29th, Kevin Feeley sold 388 shares of GeneDx stock. The shares were sold at an average price of $105.31, for a total value of $40,860.28.
• On Wednesday, July 9th, Kevin Feeley sold 5,278 shares of GeneDx stock. The shares were sold at an average price of $93.00, for a total transaction of $490,854.00.
• On Tuesday, July 1st, Kevin Feeley sold 1,344 shares of GeneDx stock. The shares were sold at an average price of $91.12, for a total transaction of $122,465.28.

GeneDx Stock Performance

Shares of GeneDx stock traded up $0.19 during mid-day trading on Monday, hitting $129.79. 264,041 shares of the stock were exchanged, compared to its average volume of 455,464. GeneDx Holdings Corp. has a 12 month low of $35.88 and a 12 month high of $136.00. The company has a 50-day simple moving average of $112.57 and a 200 day simple moving average of $93.03. The company has a market capitalization of $3.73 billion, a P/E ratio of 2,595.80 and a beta of 2.03. The company has a debt-to-equity ratio of 0.19, a quick ratio of 2.70 and a current ratio of 2.87.

GeneDx (NASDAQ:WGS - Get Free Report) last issued its quarterly earnings results on Tuesday, July 29th. The company reported $0.50 EPS for the quarter, beating analysts' consensus estimates of $0.10 by $0.40. GeneDx had a return on equity of 16.51% and a net margin of 0.39%.The company had revenue of $102.69 million during the quarter, compared to the consensus estimate of $86.00 million. GeneDx has set its FY 2025 guidance at EPS. Sell-side analysts anticipate that GeneDx Holdings Corp. will post 0.97 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

WGS has been the subject of several research reports. Piper Sandler increased their price target on shares of GeneDx from $120.00 to $140.00 and gave the company an "overweight" rating in a research report on Thursday, September 11th. Wells Fargo & Company boosted their target price on shares of GeneDx from $78.00 to $95.00 and gave the company an "equal weight" rating in a research note on Wednesday, July 30th. Guggenheim restated a "buy" rating and set a $115.00 price target (up previously from $88.00) on shares of GeneDx in a research note on Monday, June 30th. Finally, Wall Street Zen raised shares of GeneDx from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd. Six analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $104.13.

Institutional Investors Weigh In On GeneDx

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Lazard Asset Management LLC bought a new position in shares of GeneDx in the fourth quarter worth $35,000. GAMMA Investing LLC increased its position in shares of GeneDx by 151.7% during the first quarter. GAMMA Investing LLC now owns 438 shares of the company's stock valued at $39,000 after buying an additional 264 shares during the period. US Bancorp DE lifted its holdings in shares of GeneDx by 3,223.5% in the first quarter. US Bancorp DE now owns 565 shares of the company's stock worth $50,000 after buying an additional 548 shares in the last quarter. AlphaQuest LLC boosted its position in shares of GeneDx by 351.5% in the second quarter. AlphaQuest LLC now owns 763 shares of the company's stock valued at $70,000 after acquiring an additional 594 shares during the period. Finally, KBC Group NV purchased a new position in GeneDx during the first quarter valued at approximately $81,000. Institutional investors own 61.72% of the company's stock.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.